How to Value a Hospice Inpatient Facility (GIP) in 2026

General Inpatient (GIP) hospice facilities are one of the most specialized — and most misunderstood — assets in healthcare M&A. When most people think of hospice, they think of home-based care: a nurse visiting a patient at their residence. GIP is fundamentally different. These are freestanding inpatient units (or dedicated wings within hospitals or skilled nursing facilities) that provide 24-hour acute symptom management for hospice patients whose needs cannot be met at home. Pain crises, intractable nausea, respiratory distress, acute delirium — conditions that require continuous nursing intervention.

Freestanding GIP facilities typically trade at 8-14x EBITDA, making them among the highest-valued assets in the hospice sector. The premium reflects scarcity (fewer than 300 freestanding GIP facilities exist nationally), higher per diem reimbursement, and the operational complexity that creates barriers to entry. But the valuation also carries significant regulatory risk that buyers must understand deeply.

Why GIP Commands Premium Multiples

The economics of GIP versus routine home hospice care explain the valuation gap. Medicare reimburses routine home care (RHC) at approximately $200-$215 per day in 2026. General Inpatient Care reimburses at $800-$1,100 per day, depending on the geographic wage index. That's a 4-5x premium per patient day. For a 20-bed facility running at 80% occupancy, the math is compelling: roughly $4.7M-$6.4M in annual revenue from GIP days alone.

But revenue is only half the story. GIP facilities also serve as the clinical hub for a broader hospice agency operation. Most freestanding GIP facilities are affiliated with (or owned by) a hospice agency that also provides routine home care, continuous home care, and respite care. The GIP facility anchors the clinical program, provides a referral draw for hospitals and skilled nursing facilities, and creates a clinical infrastructure that supports the entire census.

This is why buyers rarely acquire a GIP facility in isolation. The facility is typically sold as part of a hospice platform, and the combined entity — home-based program plus inpatient facility — commands a premium over what either would fetch separately. The inpatient capability differentiates the hospice from the hundreds of home-only agencies competing for referrals.

The Core Valuation Metrics

Bed count and licensure. Freestanding GIP facilities typically range from 8 to 30 beds, with 12-20 being the most common for purpose-built hospice inpatient units. The Certificate of Need (CON) status matters enormously. In CON states, the regulatory barrier to building new beds is high, which means existing licensed beds have scarcity value above and beyond the operating business. In non-CON states, the barrier is lower but still significant (zoning, construction, staffing). A 16-bed facility in a CON state is worth materially more than the same facility in a non-CON state, all else equal.

Average occupancy rate. This is the metric that drives revenue and tells you whether the facility has sufficient referral relationships. An average occupancy of 75-85% is strong for GIP. Above 85% suggests the facility is capacity-constrained and could justify expansion. Below 65%, and you need to understand why — is it a referral problem, a staffing problem, or a market saturation problem? Buyers typically model acquisition value at the trailing 12-month average occupancy, not at theoretical capacity.

Average length of stay (ALOS).For GIP patients, the typical ALOS is 5-7 days. This is one of the most scrutinized metrics in hospice M&A because it has direct regulatory implications. Medicare defines GIP as appropriate for acute symptom management that cannot be managed in another setting. If a facility's ALOS is consistently above 8-10 days, it raises questions about whether patients are being appropriately classified — and that's exactly the kind of pattern that attracts OIG (Office of Inspector General) attention.

Payer mix. Most GIP revenue comes from Medicare (the Medicare Hospice Benefit covers GIP days). Medicaid covers a smaller percentage, and commercial insurance coverage for hospice inpatient care varies. A facility with 90%+ Medicare revenue is typical. The key variable is the Medicare Advantage (MA) penetration in the market. MA plans have been increasingly routing hospice beneficiaries through their managed care networks, and MA plan reimbursement for GIP can be lower than traditional Medicare. Markets with high MA penetration require careful analysis of the actual per diem rates being paid, not just the published Medicare rates.

Staffing Model and Costs

GIP facilities are nursing-intensive operations. The staffing model typically requires a minimum RN-to-patient ratio (commonly 1:5 or 1:6 during day shifts, with lower ratios overnight), plus certified nursing assistants, a medical director (physician), chaplain, social worker, and administrative staff. Labor represents 55-70% of operating costs for most GIP facilities.

The staffing challenge in 2026 is acute and directly impacts valuation. The national nursing shortage hits hospice particularly hard because GIP nursing requires specialized skills (symptom management, comfort care, family support) that not all nurses possess or want to develop. A facility with stable RN staffing — low turnover, experienced team, no agency dependence — is worth significantly more than one relying on travel nurses and staffing agencies to fill shifts.

I've seen GIP facilities with identical bed counts and occupancy rates receive 2-3x EBITDA different offers based on staffing stability alone. A buyer who inherits a stable nursing team inherits a functioning facility. A buyer who inherits 40% agency staffing inherits a cost restructuring problem and a quality risk.

The OIG Scrutiny Factor

This is where GIP valuation gets complicated, and it's where I spend the most time in due diligence. The Office of Inspector General has identified GIP level of care determinations as a fraud and abuse risk area. Their concern: some hospice providers are classifying patients at the GIP level (at $800-$1,100/day) when those patients could be managed at the routine home care level (at $200/day).

The regulatory risk is not theoretical. OIG audits, Medicare Administrative Contractor (MAC) reviews, and qui tam whistleblower actions have targeted GIP billing patterns. Facilities with high GIP utilization rates (the percentage of total patient days billed at the GIP level versus routine home care) face heightened scrutiny. The national average for GIP days as a percentage of total hospice days is approximately 2-4%. A facility or affiliated agency running significantly above that benchmark needs a compelling clinical justification.

For buyers, the diligence on GIP billing compliance is non-negotiable. You need to review:

• GIP admission criteria and clinical documentation standards
• The process for determining when a patient should transition from GIP back to routine home care
• Any history of MAC audits, overpayment determinations, or recoupments
• GIP utilization rate relative to the national benchmark
• Compliance program documentation, including internal auditing of GIP level of care

A facility with clean compliance history and GIP utilization within normal ranges is a confident buy. A facility with a history of MAC audit issues or utilization rates that look aggressive will get discounted 20-30% — or walked away from entirely.

Facility Condition and Real Estate

Unlike home-based hospice agencies (which are essentially license-plus-staff businesses), GIP facilities have a significant real estate component. The physical plant matters — both for clinical operations and for the patient and family experience.

Purpose-built hospice inpatient facilities with private rooms, family overnight accommodations, gardens or outdoor spaces, and a residential (rather than institutional) feel command premiums. Families choosing hospice inpatient care are making one of the most emotional decisions of their lives, and the environment matters to referral sources, families, and surveyors.

The real estate itself can be structured as owned or leased. Buyer preferences vary: some want to acquire the real estate (adds asset value and eliminates lease risk), others prefer to lease (lower upfront capital, higher return on invested equity). In either case, the facility condition assessment is critical. Deferred maintenance on a healthcare facility is expensive to remediate and can trigger survey deficiencies.

Who Buys GIP Facilities

The buyer pool for freestanding GIP facilities is relatively concentrated:

National hospice platforms (Amedisys/UnitedHealth, VITAS/Kindred, Compassus, Enhabit) are the primary buyers. They acquire GIP facilities to strengthen their clinical programs in target markets and to differentiate their service offering from home-only competitors. These buyers pay 10-14x EBITDA for well-run facilities in attractive markets.

Regional hospice operators seeking to add inpatient capability are active buyers, though they typically operate at lower multiples (8-11x EBITDA). For a regional operator, the GIP facility is transformative — it elevates their clinical program and opens referral relationships with hospitals that prefer partners with inpatient capacity.

Private equity firms building hospice platforms view GIP facilities as strategic differentiators. PE buyers are willing to pay premium multiples if the facility anchors a broader hospice platform play in a desirable market.

What Destroys GIP Facility Value

Compliance issues. Any history of OIG investigations, MAC audit recoupments, or whistleblower actions is potentially fatal to a transaction. Even resolved issues create indemnification demands that can eat into proceeds.

Survey deficiencies. CMS Conditions of Participation surveys (conducted by state survey agencies) that result in condition-level deficiencies or immediate jeopardy findings signal operational problems. A clean survey history over 3+ years is one of the most reassuring data points a buyer can see.

Staffing instability. As noted above, heavy reliance on agency nurses is a red flag. It increases costs, introduces quality variability, and signals that the facility cannot attract and retain its own clinical team.

Declining occupancy. A GIP facility with occupancy trending downward over 12-24 months has a referral problem, a reputation problem, or a market problem. Buyers will project future performance based on the trend, not the peak.

The Bottom Line

Freestanding GIP hospice facilities are rare, high-value assets in healthcare M&A. The combination of limited national supply, premium Medicare reimbursement, high barriers to entry, and strategic importance to hospice platforms creates a seller-friendly environment. But the valuation is only as strong as the compliance foundation. A facility with clean billing practices, stable staffing, strong occupancy, and appropriate GIP utilization rates will command 10-14x EBITDA from motivated buyers. A facility with compliance shadows, staffing problems, or aggressive utilization patterns will face heavy discounts or deal failure. In GIP more than almost any other healthcare vertical, the regulatory diligence is not a formality — it's the entire ballgame.